Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2016

View Archived Issues

Otsuka tuberculosis candidate granted U.S. orphan drug designation

DynPort Vaccine Company plague vaccine granted FDA orphan drug status

Neutralizing human MAbs protect against infection and maternal-fetal transmission of ZIKV in vivo

Ortho-McNeil-Janssen Pharmaceuticals and KU Leuven patent dengue viral replication inhibitors

Roche and Genentech disclose ERalpha ligands

Cardiome Pharma launches Xydalba in U.K.

FDA accepts durvalumab BLA for urothelial cancer

GlaxoSmithKline describes KMO inhibitors

3D microtissue engineering used to generate hypertrophic cardiomyopathy cardiomyocytes

Soligenix reports long-term follow-up data from phase II trial of SGX-942 for oral mucositis

New U.K. alliance established to accelerate development of treatments for arthritis

SNPs in BDNF and GSK-3beta may be associated with bipolar disorder

AstraZeneca initiates phase I study of abediterol and AZD-7594

E2F4 activation shows promise for SCI recovery

Phase III trials show no benefit in adding Fovista to Lucentis for wet AMD

New MGL inhibitor shows promise for the treatment of pain

Valeant Pharmaceuticals reports positive results from phase III study of IDP-118

Synergy reports results from first phase III trial of plecanatide for IBS-C

BioInvent terminates phase II study of BI-505 in multiple myeloma

New phase I trial explores use of PGT-121 for HIV prevention and therapy

Seattle Genetics initiates phase I trial of SGN-CD352A in relapsed or refractory multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...